Ilex Says Clofarabine Will Go To Oncologic Advisory Committee Dec. 1
This article was originally published in The Pink Sheet Daily
Executive Summary
The announcement follows FDA’s three-month extension of clofarabine’s review deadline. The pediatric leukemia agent is presumably one of two drugs scheduled for review by the Oncologic Drugs Advisory Committee on Dec. 1.